Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 9/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5246049 | 0.92 | SMPD1 (0.37) | SMPD1BRD4BRD2BRD3BRDT | |
| SCHEMBL5248314 | 0.92 | SMPD1 (0.39) | SMPD1BRD4BRD2BRD3BRDT | |
| SCHEMBL5247900 | 0.86 | SMPD1 (0.44) | SMPD1BRD4CNR2 | |
| SCHEMBL5244782 | 0.85 | SMPD1 (0.36) | SMPD1BRD4 | |
| SCHEMBL5247618 | 0.85 | SMPD1 (0.43) | SMPD1BRD4CNR2 | |
| SCHEMBL3116956 | 0.85 | SMPD1 (0.40) | SMPD1BRD4CNR2BRD2BRD3 | |
| SCHEMBL5248117 | 0.84 | BRD4 (0.38) | SMPD1BRD4BRD2BRD3BRDT | |
| SCHEMBL5243860 | 0.84 | SMPD1 (0.42) | SMPD1BRD4CNR2 | |
| SCHEMBL5249218 | 0.84 | CNR2 (0.41) | SMPD1BRD4CNR2 | |
| SCHEMBL5244569 | 0.83 | SMPD1 (0.41) | SMPD1BRD4CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | SMPD1 4285/4885BRD4 700/4885NPC1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.